Search results for " acute"

showing 10 items of 972 documents

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

Minimal clinically important difference and minimal detectable change of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0…

2020

Objectives: The aim of this study is to estimate a minimal clinically important difference (MCID) and a minimal detectable change (MDC) of the 12-item WHODAS 2.0 amongst patients with chronic musculoskeletal pain. Design: Cross-sectional cohort study. Setting: Outpatient Physical and Rehabilitation Medicine clinic. Subjects: A total of 1988 consecutive patients with musculoskeletal pain. Interventions: A distribution-based approach was employed to estimate a minimal clinically important difference, a minimal detectable change, and a minimal detectable percent change (MDC%). Results: The mean age of the patients was 48 years, and 65% were women. The average intensity of pain was 6,3 (2.0) po…

MaleMusculoskeletal painSchedule2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WHODASPhysical Therapy Sports Therapy and Rehabilitationminimal detectable changetuki- ja liikuntaelimetWorld healthDisability assessmentCohort StudiesDisability EvaluationMusculoskeletal PainHumansMedicineskin and connective tissue diseasesmusculoskeletal painPain Measurementbusiness.industryMinimal clinically important differenceminimal clinically important differenceRehabilitationkipuMiddle AgedCross-Sectional StudiesPhysical therapyFemalesense organsWhodasChronic PainbusinessData Collection toolsClinical Rehabilitation
researchProduct

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

2020

Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers wer…

0301 basic medicineMaleAntibodies ViralSeverity of Illness IndexGastroenterologylaw.invention0302 clinical medicinelaw030212 general & internal medicinebiologyInflammatory biomarkersMiddle AgedIntensive care unitHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusFemaleAntibodyCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyPneumonia ViralNeutralizing antibodiesArticleVirus03 medical and health sciencesBetacoronavirusYoung AdultVirologyInternal medicineSeverity of illnessmedicineHumansPandemicsAgedRetrospective StudiesInflammationbusiness.industrySARS-CoV-2C-reactive proteinCOVID-19Retrospective cohort studyAntibodies NeutralizingFerritinbiology.proteinBinding Sites AntibodybusinessBiomarkers
researchProduct

Editorial: The Challenge of New Therapeutic Approaches for Unmet Therapeutic Needs

2020

Pharmacologydrug-designmedicine.medical_specialty2019-20 coronavirus outbreakdrug-design; efficacy/risk ratio; innovative therapies; pharmaceutical innovations; pharmacology innovationCoronavirus disease 2019 (COVID-19)business.industrypharmacology innovationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)lcsh:RM1-950lcsh:Therapeutics. PharmacologyInnovative Therapiesinnovative therapiespharmaceutical innovationsmedicinePharmacology (medical)Intensive care medicinebusinessPharmaceutical innovationsefficacy/risk ratio
researchProduct

Bioactive pyrrole-based compounds with target selectivity

2020

The discovery of novel synthetic compounds with drug-like properties is an ongoing challenge in medicinal chemistry. Natural products have inspired the synthesis of compounds for pharmaceutical application, most of which are based on N-heterocyclic motifs. Among these, the pyrrole ring is one of the most explored heterocycles in drug discovery programs for several therapeutic areas, confirmed by the high number of pyrrole-based drugs reaching the market. In the present review, we focused on pyrrole and its hetero-fused derivatives with anticancer, antimicrobial, and antiviral activities, reported in the literature between 2015 and 2019, for which a specific target was identified, being resp…

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antineoplastic AgentsReview ArticlePyrroleAntiviral Agentschemistry.chemical_compoundAnti-Infective AgentsDrug DiscoveryHumansPyrrolesMolecular Targeted TherapyAntiviralTargeted compoundsPyrrolePharmacologyDrug discoveryChemistryOrganic ChemistryCOVID-19Biological activityGeneral MedicineAntimicrobialSettore CHIM/08 - Chimica FarmaceuticaCombinatorial chemistryAnticancerDrug DesignAntimicrobialPharmacophoreSelectivityEuropean Journal of Medicinal Chemistry
researchProduct

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leu…

2015

Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell tr…

AdultMalemedicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentSalvage therapyTretinoinComorbidityKaplan-Meier EstimateAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansSalvage TherapyMitoxantroneChemotherapybusiness.industryRemission InductionCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyArticlesMiddle Agedmedicine.diseaseGemtuzumab3. Good healthSurgeryTransplantationConsolidation ChemotherapyLeukemiaLeukemia Myeloid AcuteAminoglycosidesTreatment Outcome030220 oncology & carcinogenesisCytarabineFemaleMitoxantronebusiness030215 immunologymedicine.drugHaematologica
researchProduct

STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

2012

Abstract MOZ-TIF2 is a leukemogenic fusion oncoprotein that confers self-renewal capability to hematopoietic progenitor cells and induces acute myelogenous leukemia (AML) with long latency in bone marrow transplantation assays. Here, we report that FLT3-ITD transforms hematopoietic cells in cooperation with MOZ-TIF2 in vitro and in vivo. Coexpression of FLT3-ITD confers growth factor independent survival/proliferation, shortens disease latency, and results in an increase in the number of leukemic stem cells (LSC). We show that STAT5, a major effector of aberrant FLT3-ITD signal transduction, is both necessary and sufficient for this cooperative effect. In addition, STAT5 signaling is essent…

Cancer ResearchMyeloidOncogene Proteins Fusionmedicine.medical_treatmentArticleMyelogenousMicehemic and lymphatic diseasesmedicineSTAT5 Transcription FactorAnimalsSTAT5Mice Inbred BALB CbiologyGrowth factormedicine.diseaseFlow CytometryHaematopoiesisLeukemiaBlotting SouthernLeukemia Myeloid Acutemedicine.anatomical_structureCell Transformation NeoplasticOncologyCancer researchbiology.proteinNeoplastic Stem CellsSignal transductionStem cellSignal TransductionCancer research
researchProduct

Pooled analysis of monocyte distribution width in subjects with SARS‐CoV‐2 infection

2021

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryLetter to the EditorsMonocytesLeukocyte CountMDWmedicineDistribution (pharmacology)Humansmonocyte distribution widthLetter to the EditorCell SizeBiochemistry medicalbusiness.industrySARS-CoV-2MonocyteBiochemistry (medical)COVID-19Meta-analysis monocyte distribution width MDW SARS-CoV-2HematologyGeneral MedicinePrognosisVirologyMeta-analysisPooled analysismedicine.anatomical_structurebusinessInternational Journal of Laboratory Hematology
researchProduct

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

2021

Abstract In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly in patients with severely impaired immune system. In response to that uncertainty, the Spanish Society of Hematology and Hemotherapy launched an initiative aimed to provide recommendations for vaccination of the main hematological conditions. This document is based on the available information on COVID-19 outcomes, prior knowledge on vaccination in hematological patients, recent pu…

Cancer Researchmedicine.medical_specialtyCOVID-19 VaccinesConsensusCoronavirus disease 2019 (COVID-19)myeloproliferative neoplasmSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)lymphomaReviewstem cell transplantationCOVID-19 SARS-CoV-2 vaccine acute leukemia allogeneic stem cell transplantation lymphoma myelodisplastic syndrome myeloproliferative neoplasm onco-hematology stem cell transplantation vaccination consensusallogeneic stem cell transplantationSARS-CoV-2 vaccineInternal medicinePandemicmedicineHemotherapyHumansIn patientacute leukemiaIntensive care medicineExpert TestimonyPandemicsonco-hematologyHematologySARS-CoV-2business.industryVaccinationCOVID-19Expert consensusHematologyVaccinationvaccination consensusOncologymyelodisplastic syndromebusiness
researchProduct

Acute, chronic and sublethal effects of the herbicide propanil on Daphnia magna.

2003

Acute and chronic toxicity tests with propanil were conducted on Daphnia magna. The 24 and 48 h LC50 were 43.74 and 5.01 mg/l respectively. Chronic toxicity tests were carried out using sublethal propanil concentrations (0.07, 0.10, 0.21 and 0.55 mg/l) during 21 days. The effect of propanil on survival, reproduction and growth of D. magna organisms was monitored. The parameters used to evaluate herbicide effect on reproduction were: mean total young ones per female, mean brood size, time to first reproduction, mean number broods per female and intrinsic rate of natural increase (r). Survival and growth (body length) were also determined after 21 days of exposure to the herbicide. Reproducti…

Environmental EngineeringHealth Toxicology and MutagenesisDaphnia magnaPropanilToxicologychemistry.chemical_compoundEatingAnimal sciencePropanilToxicity Tests AcuteEnvironmental ChemistryAnimalsToxicity Tests ChronicChronic toxicityEC50biologyHerbicidesReproductionPublic Health Environmental and Occupational HealthGeneral MedicineGeneral Chemistrybiology.organism_classificationPollutionchemistryCladoceraDaphniaMaximum acceptable toxicant concentrationToxicityToxicantChemosphere
researchProduct